Genomic Antibody Technology™

Genomic Antibody Technology™ (GAT) is a new way to think about immunogens. Using GAT, the immunogen is expressed in vivo and is immediately presented to the immune system. GAT requires only the amino acid sequence of your target protein. The need for peptides, recombinant proteins or protein purified from native sources is eliminated. The uncertainty that the protein may be denatured during expression or purification is eliminated. The time, effort, and resources required to synthesize peptides, express proteins and purify proteins is eliminated. Shipping of antigens is eliminated.

GAT versus Conventional Immunization

  GAT Conventional Immunization
Eliminate expression of recombinant protein antigen Available Not available
Eliminate synthesis of peptide antigen Available Not available
Eliminate purification of protein from serum, tissues, cells or other sources Available Not available
Eliminate difficult antigen preparation Available Not available
Eliminate antigen shortages Available Not available
Eliminate antigen with insufficient purity Available Not available
Eliminate the uncertainty that the antigen may be denatured during preparation Available Not available
Start immunizing without peptide or protein antigen Available Not available
Put antigen preparation on a short, predictable timeline Available Not available
Start immunization by transferring the amino acid sequence of your target protein from your computer to our server Available Not available
Ready to Order?

You can order Genomic Antibody Technology™ online by submitting your genetic sequence using your STAR Account or by emailing the GAT submission form to GAT@sdix.com. You can use a purchase order or your credit card to order online today.

Sign in to your STAR Account, or register to create one.

The latest from SDI Antibodies

  • SDI Selected as Key Supplier to SAIC-F and the National Cancer Institute for the Development of a Comprehensive Portfolio of Antibodies for use in Cancer Research. more more

  • SDI to Produce Library of Antibodies for the Study of Usher Syndrome. more more

  • SDI Enters Supply Agreement for Antibody Library for Study of Chromosome Proteins with University of North Carolina Chapel Hill more more

  • SDI Announces Progress in Advancing Clinical Biomarker Discovery, Successful Application of Technology in Cancer Biomarker Identification at M.D. Anderson Cancer Center more more

  • Strategic Diagnostics Inc. Announces Partnership with the University of Delaware and the Helen F. Graham Cancer Center to Develop Cancer Assays more more

  • SDI Announces Success in Demonstrating Utility of its Proprietary Genomic Antibody Technology™ Reagents on Clinical Samples in Cooperation with the Human Protein Atlas more more
    • Attend a Genomic Antibody Technology™ Webinar.
    • More dates coming soon.

    To register, send a message to GATWebinar@sdix.com